🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Come join our team! Clinical Research Coordinator (CRC) - Young Women's Program (#Boston, Massachusetts) #job social.icims.com/viewjob/pt1751… Dana-Farber’s Breast Oncology Center

In an interview with Dr Sarah Sammons, she discussed: ✅ The design of ReDiscover ✅ The findings presented during #ASCO25 ✅ The potential role for RLY-2608 in the treatment of patients with HR+/HER2– #BreastCancer Read more: hubs.li/Q03vCX9k0

AACR Past-President Dr. Patricia M LoRusso Personal Experiences With Cancer AACR oncodaily.com/stories/patric… #Cancer #Oncology #OncoDaily #Health #Medicine CancerWorld

Tess O'Meara, MD, MHS Read more here: onclive.com/view/t-dxd-plu…

🆕 Article in press: Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer. annalsofoncology.org/article/S0923-… FabriceAndre Elsa Bernard Barbara Pistilli

In an interview with Dr. E Mittendorf, she discussed: 🌟 How ASCO is positioning its advocacy efforts to address the long-term implications of proposed federal research funding cuts 🌟 The critical return on investment generated by the support of the NIH 🌟 And more!

Dr. E Mittendorf Read it all here: onclive.com/view/dr-mitten…

Here's the #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (June 28th-July 3rd, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Top 4 Insights from Erica Mayer´s Talk 👇 Adjuvant CDK4/6 inhibition: Who needs which agent—and for how long? Erica Mayer, MD, of Dana-Farber Cancer Institute shared critical takeaways during the Breast Cancer US Focus Meeting 2025. 🎥 The full recording of her talk is now

New 📰on racial and ethnic variation in body composition and prognosis of nonmetastatic #BreastCancer. "We found that even at the same body size measured via #BMI there are racial and ethnic differences in #adiposity and muscularity that could partially explain #disparities in

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic #BreastCancer should know. Sara Tolaney Dana-Farber hubs.li/Q03w7QkB0

New study looks at regular aspirin use, breast tumor characteristics and long-term breast cancer survival 🔓pubmed.ncbi.nlm.nih.gov/40595613/ Tengteng Wang #wendychen #kristenbrantley

True pleasure to open the 3rd Annual ADC Toxicity Summit with a workshop dedicated to improving the safety of ADCs — co-chaired with awesome colleague Elia Seguí, MD. Incredible multidisciplinary discussions and great opportunity of prolific cross-talk between academia and industry!

Breastfeeding after breast cancer in young BRCAcarriers academic.oup.com/jnci/advance-a… This international retrospective cohort study evaluated the safety of breastfeeding after breast cancer in women with germline BRCA🧬 pathogenic or likely pathogenic variants. Among 474 BRCA

Q-TWiST Analysis to Assess Benefit-Risk of Sacituzumab Govitecan in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer. Read the full article. brnw.ch/21wU19J

Happening now! The inaugural ACGME accredited CNS Metastases Seminar Series Dana-Farber’s Breast Oncology Center Dana-Farber First up Dr Ayal Aizer discussing novel updates in Radiation Oncology in Brain Metastases. About 250k Brain Mets in US per year. More research needed.

Wonderful editorial by Marko Velimirovic MD MMSc & Jame Abraham, MD, FACP accompanying our JCO Oncology Practice review on the evolution of HER2 testing in oncology. Recommend reading to anyone interested in a recap of the epic journey of HER2 as a biomarker over the past 30 years. ascopubs.org/doi/10.1200/OP…

Dr. Sarah Sammons (Dr Sarah Sammons) launched the inaugural ACGME accredited #CNS Metastases Seminar Series. Our first speaker is Dr Ayal Aizer (Ayal Aizer), Director of Brain #RadiationOncology Brigham and Women's Hospital and Dana-Farber. He discussed recent advances in radiation therapy in

Dr Sarah Tolaney (Sara Tolaney) discusses #ASCENT04 Data in First-Line PD-L1+ metastatic #TNBC with Targeted Oncology. Watch the video here: targetedonc.com/view/dr-tolane…

IBC East Faculty Spotlight! Let's see if you can spot Dr. E Mittendorf lie! Comment below what you think the lie is! Interested to see what IBCE has in store? View the agenda here: tinyurl.com/4rexsusu